Detalhe da pesquisa
1.
Effects of tolvaptan discontinuation in patients with autosomal dominant polycystic kidney disease: a post hoc pooled analysis.
BMC Nephrol
; 24(1): 182, 2023 06 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-37349694
2.
Development of the Autosomal Dominant Polycystic Kidney Disease Impact Scale: A New Health-Related Quality-of-Life Instrument.
Am J Kidney Dis
; 71(2): 225-235, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29150246
3.
Prevalence of autosomal dominant polycystic kidney disease in the European Union.
Nephrol Dial Transplant
; 32(8): 1356-1363, 2017 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27325254
4.
Albuminuria and tolvaptan in autosomal-dominant polycystic kidney disease: results of the TEMPO 3:4 Trial.
Nephrol Dial Transplant
; 31(11): 1887-1894, 2016 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-26681730
5.
Tolvaptan in patients with autosomal dominant polycystic kidney disease.
N Engl J Med
; 367(25): 2407-18, 2012 Dec 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-23121377
6.
Therapeutic Area Data Standards for Autosomal Dominant Polycystic Kidney Disease: A Report From the Polycystic Kidney Disease Outcomes Consortium (PKDOC).
Am J Kidney Dis
; 66(4): 583-90, 2015 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-26088508
7.
Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function.
Am J Kidney Dis
; 65(6): 833-41, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-25600953
8.
Short-term renal hemodynamic effects of tolvaptan in subjects with autosomal dominant polycystic kidney disease at various stages of chronic kidney disease.
Kidney Int
; 84(6): 1278-86, 2013 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-23903369
9.
Clinical course of patients with hyponatremia and decompensated systolic heart failure and the effect of vasopressin receptor antagonism with tolvaptan.
J Card Fail
; 19(6): 390-7, 2013 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-23743487
10.
Development of a Patient-Reported Outcomes Tool to Assess Pain and Discomfort in Autosomal Dominant Polycystic Kidney Disease.
Clin J Am Soc Nephrol
; 18(2): 213-222, 2023 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36754008
11.
Technical Review of Clinical Outcomes Assessments Across the Continuum of Alzheimer's Disease.
Neurol Ther
; 12(2): 571-595, 2023 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-36790638
12.
Assessing What Matters to People Affected by Alzheimer's Disease: A Quantitative Analysis.
Neurol Ther
; 12(2): 505-527, 2023 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-36763306
13.
Pooled Data Analysis of the Long-Term Treatment Effects of Tolvaptan in ADPKD.
Kidney Int Rep
; 7(5): 1037-1048, 2022 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-35570988
14.
Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease.
Kidney Int
; 80(3): 295-301, 2011 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-21544064
15.
Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study.
Am J Kidney Dis
; 57(5): 692-9, 2011 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-21333426
16.
Effects of tolvaptan on dyspnoea relief from the EVEREST trials.
Eur Heart J
; 30(18): 2233-40, 2009 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-19561338
17.
Assessing what matters most to patients with or at risk for Alzheimer's and care partners: a qualitative study evaluating symptoms, impacts, and outcomes.
Alzheimers Res Ther
; 12(1): 90, 2020 07 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-32731886
18.
Economic Burden and Health-Related Quality of Life Associated with Current Treatments for Anaemia in Patients with CKD not on Dialysis: A Systematic Review.
Pharmacoecon Open
; 3(4): 463-478, 2019 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-30968369
19.
Economic and quality of life burden of anemia on patients with CKD on dialysis: a systematic review.
J Med Econ
; 22(6): 593-604, 2019 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-30813807
20.
Clinical implications of QRS duration in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction.
JAMA
; 299(22): 2656-66, 2008 Jun 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-18544725